Julie Torode Discusses the WHO Cervical Cancer Elimination Strategy

Article

The director of special projects at the Union for International Cancer Control spoke about the strategy released by the World Health Organization and what needs to occur to achieve the goals laid out by the organization.

Following a call from the World Health Organization (WHO) Director General in 2018, a global strategy was developed by the organization to accelerate the elimination of cervical cancer as a public health problem.

The strategy established goals and targets from 2020 to 2030 with a focus on 3 key pillars, including prevention through HPV vaccination, screening and treatment of pre-cancerous lesions, and management of invasive cervical cancer, including access to palliative care.

To eliminate cervical cancer, the WHO indicated that all countries must reach and maintain an incidence below 4 per 100,000 women-years.

“Ninety percent of girls should be fully vaccinated by 15 years of age, 70% of women should be screened at least twice with a high-performance test by age 45 and 90% of women with precancer or cancer should receive the appropriate care and treatment, including palliative care,” Tedros Adhanom Ghebreyesus, PhD, MSc, BSc, director-general of WHO, explained during a WHO video. “We believe all countries can meet these ambitious goals.”

According to the WHO, achieving these specified targets would yield reductions in both incidence and mortality. Further, by 2030, the median cervical cancer incidence rate would fall by 10%, setting the world on the path to avert 70 million cases in the century.

In an interview with CancerNetwork®, Julie Torode, director of special projects at the Union for International Cancer Control (UICC), discussed the strategy further and how individuals can aid in advocating for the advancement of this global strategy.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

73rd World Health Assembly Decisions [news release]. Published August 7, 2020. Accessed August 20, 2020. https://www.who.int/news-room/feature-stories/detail/73rd-world-health-assembly-decisions

Recent Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content
Subgroup data indicate a positive efficacy trend for TG4001 plus avelumab among patients with cervical cancer.

Cancer Vaccine Combo Does Not Improve PFS in Cervical/Anogenital Tumors

Russ Conroy
October 15th 2024
Article

Subgroup data indicate a positive efficacy trend for TG4001 plus avelumab among patients with cervical cancer.

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer

Jyoti Mayadev, MD
January 22nd 2024
Podcast

The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.

Pembrolizumab/CRT Improve Survival in High-Risk Locally Advanced Cervical Cancer

Pembrolizumab/CRT Improve Survival in High-Risk Locally Advanced Cervical Cancer

Kristi Rosa
September 14th 2024
Article

Pembrolizumab combination improved efficacy outcomes vs chemoradiotherapy alone in patients with advanced cervical cancer.

Julianne Cooley, MS, spoke with CancerNetwork® about older patients with later stage cervical cancer who have lower survival rates compared with their younger counterparts.

Oncology Peer Review On-The-Go Podcast: Cervical Cancer Screenings/Survival in Those 65+ Years

Julianne Cooley, MS
February 2nd 2023
Podcast

Julianne Cooley, MS, spoke with CancerNetwork® about older patients with later stage cervical cancer who have lower survival rates compared with their younger counterparts.

Approval of the self-collection solution may reduce barriers to sample collection and increase access to cervical cancer screening.

FDA Approves HPV Self-Collection Solution for Cervical Cancer Detection

Russ Conroy
May 15th 2024
Article

Approval of the self-collection solution may reduce barriers to sample collection and increase access to cervical cancer screening.

The CheckMate 358 trial assessed various doses of nivolumab with or without ipilimumab for recurrent or metastatic cervical cancer.

Nivolumab ± Ipilimumab Yields Durable Responses in Cervical Cancer

Ariana Pelosci
May 13th 2024
Article

The CheckMate 358 trial assessed various doses of nivolumab with or without ipilimumab for recurrent or metastatic cervical cancer.